197 related articles for article (PubMed ID: 21450622)
1. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and arterial interactions in end-stage renal disease.
London GM; Guerin AP; Marchais SJ; Pannier B; Safar ME; Day M; Metivier F
Kidney Int; 1996 Aug; 50(2):600-8. PubMed ID: 8840292
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
5. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
Weidemann F; Breunig F; Beer M; Sandstede J; Turschner O; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
Circulation; 2003 Sep; 108(11):1299-301. PubMed ID: 12952834
[TBL] [Abstract][Full Text] [Related]
6. Arterial remodelling in Fabry disease.
Boutouyrie P; Laurent S; Laloux B; Lidove O; Grunfeld JP; Germain DP
Acta Paediatr Suppl; 2002; 91(439):62-6. PubMed ID: 12572845
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
9. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents.
Lanes R; Gunczler P; Lopez E; Esaa S; Villaroel O; Revel-Chion R
J Clin Endocrinol Metab; 2001 Mar; 86(3):1061-5. PubMed ID: 11238486
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
Schwarting A; Dehout F; Feriozzi S; Beck M; Mehta A; Sunder-Plassmann G;
Clin Nephrol; 2006 Aug; 66(2):77-84. PubMed ID: 16939062
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
12. Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end-stage renal failure patients.
De Lima JJ; Vieira ML; Viviani LF; Medeiros CJ; Ianhez LE; Kopel L; de Andrade JL; Krieger EM; Lage SG
Nephrol Dial Transplant; 2002 Apr; 17(4):645-51. PubMed ID: 11917059
[TBL] [Abstract][Full Text] [Related]
13. Enhanced radial late systolic pressure augmentation in hypertensive patients with left ventricular hypertrophy.
Hashimoto J; Watabe D; Hatanaka R; Hanasawa T; Metoki H; Asayama K; Ohkubo T; Totsune K; Imai Y
Am J Hypertens; 2006 Jan; 19(1):27-32. PubMed ID: 16461187
[TBL] [Abstract][Full Text] [Related]
14. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters.
Lanes R; Soros A; Flores K; Gunczler P; Carrillo E; Bandel J
J Clin Endocrinol Metab; 2005 Jul; 90(7):3978-82. PubMed ID: 15870123
[TBL] [Abstract][Full Text] [Related]
15. [Local pulse pressure and regression of arterial wall hypertrophy during antihypertensive treatment. CELIMENE study. The Celiprolol Intima-Media Enalapril Efficacy study].
Boutouyrie P; Bussy C; Tropeano AI; Hayoz D; Hengstler J; Dartois N; Laloux B; Brunner H; Laurent S
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):911-5. PubMed ID: 10989729
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal association of ambulatory pulse pressure with left ventricular mass and vascular hypertrophy in essential hypertension.
Khattar RS; Acharya DU; Kinsey C; Senior R; Lahiri A
J Hypertens; 1997 Jul; 15(7):737-43. PubMed ID: 9222941
[TBL] [Abstract][Full Text] [Related]
17. Vasculopathy in Turner syndrome: arterial dilatation and intimal thickening without endothelial dysfunction.
Ostberg JE; Donald AE; Halcox JP; Storry C; McCarthy C; Conway GS
J Clin Endocrinol Metab; 2005 Sep; 90(9):5161-6. PubMed ID: 15985480
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular hypertrophy and arterial hypertrophy.
Mallion JM; Baguet JP; Siché JP; Tremel F; De Gaudemaris R
Adv Exp Med Biol; 1997; 432():123-33. PubMed ID: 9433519
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy.
Shah JS; Elliott PM
Acta Paediatr Suppl; 2005 Mar; 94(447):11-4; discussion 9-10. PubMed ID: 15895705
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.
Frustaci A; Verardo R; Galea N; Alfarano M; Magnocavallo M; Marchitelli L; Sansone L; Belli M; Cristina M; Frustaci E; Russo MA; Chimenti C
J Am Heart Assoc; 2024 Apr; 13(8):e032734. PubMed ID: 38563373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
